Anupam Rasayan
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Anupam Rasayan's recent strategic acquisitions and diversification into high-growth segments are pivotal in shaping its financial outlook. Management's confidence stems from the successful integration of Jayhawk Fine Chemicals and the anticipated benefits from the Bliss GVS Pharma acquisition, which are expected to enhance manufacturing capabilities and expand into regulated markets. This positions the company to achieve a projected revenue exceeding INR 4,000 crores with an EBITDA of approximately INR 834 crores, reflecting a robust growth trajectory. Vista's forecast aligns with these developments, anticipating a 20-30% CAGR driven by the Pharma and Polymer segments, supported by a strong pipeline of over 90 new products. However, the company faces challenges from competitive pressures in the specialty chemicals sector, which may impact pricing power. The macroeconomic environment in India remains favorable, with strong manufacturing activity and contained inflation, further supporting Anupam's growth. Over the next 12-24 months, key opportunities include leveraging its expanded capacity and entering new markets, while watchpoints include execution risks related to plant approvals and maintaining operational efficiencies amidst competitive dynamics
Why We Like This Stock
- Successful integration of Jayhawk Fine Chemicals and anticipated synergies from the Bliss GVS Pharma acquisition are expected to enhance growth and profitability
- A strong order book of ₹14,646 Crores provides significant revenue visibility, supporting a projected revenue exceeding INR 4,000 crores
- Management's focus on high-value segments and a robust pipeline of over 90 new products positions the company for sustained growth
Things To Watch Out For
- Competitive pressures in the specialty chemicals sector may limit pricing power and impact margins
- Execution risks related to plant approvals could delay anticipated growth and operational efficiencies
- Slowing revenue growth relative to historical performance may raise concerns among investors
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 1,475 | 1,437 | 2,365 | 2,723 | 3,651 |
| Profit Before Tax (Cr.) | 236 | 198 | 254 | 346 | 446 |
| PBT Margin | 16.0% | 13.8% | 1074.0% | 12.7% | 12.2% |
| Net Profit (Cr.) | 189 | 154 | 202 | 274 | 262 |
| Earnings Per Share | 13.2 | 7.7 | 13.2 | 17.9 | 23.0 |
Analyst Recommendations
No analyst recommendations available.
Company Overview
Show Company Profile
Anupam Rasayan India Ltd engages in the custom synthesis and manufacturing of specialty chemicals in India, Europe, Japan, Singapore, China, North America, and internationally. It operates through two segments: Life Science related Specialty Chemicals and Other Specialty Chemicals. The company offers life science related specialty chemicals, such as agro intermediates and agro active ingredients for the agrochemicals industry; anti-bacterial and ultraviolet protection intermediates and ingredients for the personal care industry; and intermediates and key starting materials for active pharmaceutical ingredients. It provides other specialty chemicals used in various end-user segments, including specialty pigments, specialty dyes, and polymer additives. The company was incorporated in 1984 and is headquartered in Surat, India.